Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy.
J Bousquet, A Hejjaoui, A M Clauzel...
https://pubmed.ncbi.nlm.nih.gov/3204255/Actively Recruiting
Led by Inmunotek S.L. · Updated on 2025-05-13
150
Participants Needed
32
Research Sites
N/A
Total Duration
Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy SCIT in people aged 12 to 65 who have allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The study focuses on patients sensitized to specific house dust mites, Dermatophagoides pteronyssinus andor Dermatophagoides farinae. This is a phase 3, double-blind, placebo-controlled, randomized trial conducted at multiple centers. Participants will be randomly assigned to one of three groups two receive different doses of SCIT 10,000 TUmL or 30,000 TUmL of allergenic extract, and one receives a placebo injection without active ingredients. Treatment lasts for one year, with doses administered subcutaneously. The study compares the two active treatment groups to the placebo group to determine which dose may be more effective and safe. During the trial, participants will be closely monitored for symptoms and medication use, assessed by the Combined Symptoms and Medication Score CSMS over 12 months. Researchers will also track medication-free days, symptom-free days, quality of life related to asthma and rhinitis, adverse events, and immunological responses. Participants will log symptoms and medication use via smartphone. Safety and treatment effects will be evaluated throughout the study period.
CONDITIONS
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
M
Miguel Casanovas, MD PhD
R
Raquel Caballero, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Inmunotek S.L.
Lead Sponsor
BioClever 2005 S.L.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 year
Participants receive subcutaneous immunotherapy with either the active allergenic extract or placebo to treat their allergy to dust mites.
Regular visits for injection and monitoring during treatment
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
J Bousquet, A Hejjaoui, A M Clauzel...
https://pubmed.ncbi.nlm.nih.gov/3204255/R Cardona, E Lopez, J Beltrán...
https://pubmed.ncbi.nlm.nih.gov/23265265/Juan José Yepes-Núñez, Carolina Gómez, Yeinis Espinoza...
https://pubmed.ncbi.nlm.nih.gov/24967933/M Branco Ferreira, A Spínola Santos, M C Pereira Santos...
https://pubmed.ncbi.nlm.nih.gov/15808114/G L Piacentini, L Vicentini, P Mazzi...
https://pubmed.ncbi.nlm.nih.gov/9645592/Inmunotek S.L.
Lead Sponsor
BioClever 2005 S.L.
Collaborating Sponsor